1. Home
  2. CDNA vs VSAT Comparison

CDNA vs VSAT Comparison

Compare CDNA & VSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDNA
  • VSAT
  • Stock Information
  • Founded
  • CDNA 1998
  • VSAT 1986
  • Country
  • CDNA United States
  • VSAT United States
  • Employees
  • CDNA N/A
  • VSAT N/A
  • Industry
  • CDNA Medical Specialities
  • VSAT Radio And Television Broadcasting And Communications Equipment
  • Sector
  • CDNA Health Care
  • VSAT Technology
  • Exchange
  • CDNA Nasdaq
  • VSAT Nasdaq
  • Market Cap
  • CDNA 1.0B
  • VSAT 1.2B
  • IPO Year
  • CDNA 2014
  • VSAT 1996
  • Fundamental
  • Price
  • CDNA $19.07
  • VSAT $14.40
  • Analyst Decision
  • CDNA Buy
  • VSAT Buy
  • Analyst Count
  • CDNA 6
  • VSAT 7
  • Target Price
  • CDNA $30.33
  • VSAT $20.00
  • AVG Volume (30 Days)
  • CDNA 989.3K
  • VSAT 4.9M
  • Earning Date
  • CDNA 07-30-2025
  • VSAT 08-06-2025
  • Dividend Yield
  • CDNA N/A
  • VSAT N/A
  • EPS Growth
  • CDNA N/A
  • VSAT N/A
  • EPS
  • CDNA 1.07
  • VSAT N/A
  • Revenue
  • CDNA $346,421,000.00
  • VSAT $4,519,571,000.00
  • Revenue This Year
  • CDNA $13.31
  • VSAT $4.46
  • Revenue Next Year
  • CDNA $15.46
  • VSAT $3.58
  • P/E Ratio
  • CDNA $17.90
  • VSAT N/A
  • Revenue Growth
  • CDNA 25.92
  • VSAT 5.50
  • 52 Week Low
  • CDNA $14.09
  • VSAT $6.69
  • 52 Week High
  • CDNA $34.84
  • VSAT $26.70
  • Technical
  • Relative Strength Index (RSI)
  • CDNA 57.48
  • VSAT 78.34
  • Support Level
  • CDNA $18.64
  • VSAT $12.40
  • Resistance Level
  • CDNA $19.44
  • VSAT $14.76
  • Average True Range (ATR)
  • CDNA 0.75
  • VSAT 0.89
  • MACD
  • CDNA -0.05
  • VSAT 0.30
  • Stochastic Oscillator
  • CDNA 46.86
  • VSAT 93.04

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

About VSAT ViaSat Inc.

Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.

Share on Social Networks: